Journal of the American Academy of Dermatology

Article	Citations
Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases	617
Skin damage among health care workers managing coronavirus disease-2019	356
COVID-19 can present with a rash and be mistaken for dengue	313
The spectrum of COVID-19–associated dermatologic manifestations: An international registry of 716 patients from 31 countries	268
Varicella-like exanthem as a specific COVID-19–associated skin manifestation: Multicenter case series of 22 patients	262
Immune checkpoint inhibitor–related dermatologic adverse events	225
Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial	215
Hidradenitis suppurativa	204
Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies	184
A dermatologic manifestation of COVID-19: Transient livedo reticularis	166
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated	163
Pernio-like skin lesions associated with COVID-19: A case series of 318 patients from 8 countries	151
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis	146
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies	143
Hand hygiene during COVID-19: Recommendations from the American Contact Dermatitis Society	142
Dupilumab as a novel therapy for bullous pemphigoid: A multicenter case series	130
Characterization of acute acral skin lesions in nonhospitalized patients: A case series of 132 patients during the COVID-19 outbreak	130
Should biologics for psoriasis be interrupted in the era of COVID-19?	128
Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures	127
Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The “Gabrin sign”	122
Chilblains is a common cutaneous finding during the COVID-19 pandemic: A retrospective nationwide study from France	118
Chilblain-like acral lesions during the COVID-19 pandemic (“COVID toes”): Histologic, immunofluorescence, and immunohistochemical study of 17 cases	115
Oral minoxidil treatment for hair loss: A review of efficacy and safety	114
COVID-19 and racial disparities	110
Skin color in dermatology textbooks: An updated evaluation and analysis	109

Clinical and pathologic correlation of cutaneous COVID-19 vaccine reactions including V-REPP: A registry-based study	108
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1	107
Ultraviolet germicidal irradiation: Possible method for respirator disinfection to facilitate reuse during the COVID-19 pandemic	106
Acne vulgaris and risk of depression and anxiety: A meta-analytic review	103
Immune checkpoint inhibitor therapy in solid organ transplant recipients: A patient-centered systematic review	102
The Alopecia Areata Consensus of Experts (ACE) study: Results of an international expert opinion on treatments for alopecia areata	101
A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results	96
Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent	90
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 i	89
Telehealth: Helping your patients and practice survive and thrive during the COVID-19 crisis with rapid quality implementation	88
Occupational skin disease among health care workers during the coronavirus (COVID-19) epidemic	88
Standard management options for rosacea: The 2019 update by the National Rosacea Society Expert Committee	87
Cutaneous manifestations in COVID-19: Lessons learned from current evidence	87
Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features	86
Prurigo nodularis	86
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)	85
United States burden of melanoma and non-melanoma skin cancer from 1990 to 2019	85
Reply to “COVID-19 can present with a rash and be mistaken for dengue”: Petechial rash in a patient with COVID-19 infection	84
COVID-19 and immunomodulator/immunosuppressant use in dermatology	84
Leprosy: Clinical aspects and diagnostic techniques	81
Photoprotection beyond ultraviolet radiation: A review of tinted sunscreens	81
COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence	81
Visible light. Part I: Properties and cutaneous effects of visible light	80
The digital divide: How COVID-19's telemedicine expansion could exacerbate disparities	80
Prurigo nodularis	79
National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19	79
Progression of cutaneous T-cell lymphoma after dupilumab: Case review of 7 patients	77
Clinical effectiveness and cost-effectiveness of teledermatology: Where are we now, and what are the barriers to adoption?	77
Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO	75
Occupational dermatitis to facial personal protective equipment in health care workers: A systematic review	75
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study	74
Field cancerization: Definition, epidemiology, risk factors, and outcomes	73
The Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic derm	73
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations	73
Efficacy and patient-reported outcomes from a phase 2b, randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis	72
Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients	72
Infantile hemangioma. Part 1: Epidemiology, pathogenesis, clinical presentation and assessment	72
Pathophysiologic mechanisms of itch in bullous pemphigoid	72
Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study	71
Dermatology practices as vectors for COVID-19 transmission: A call for immediate cessation of nonemergent dermatology visits	71
Teledermatology in the era of COVID-19: Experience of an academic department of dermatology	70
Psychosocial and psychiatric comorbidities and health-related quality of life in alopecia areata: A systematic review	69
Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study	69
The global, regional, and national burden of psoriasis in 195 countries and territories, 1990 to 2017: A systematic analysis from the Global Burden of Disease Study 2017	68
Hidradenitis suppurativa	68
Behavioral considerations and impact on personal protective equipment use: Early lessons from the coronavirus (COVID-19) pandemic	67
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3	66
Characterizing the adverse dermatologic effects of hydroxychloroquine: A systematic review	66
Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): A prospective study from China and Italy	65
Facial and neck erythema associated with dupilumab treatment: A systematic review	65

Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?	64
Cutaneous manifestations of COVID-19: A preliminary review	64
No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis	62
Cutaneous adverse events caused by immune checkpoint inhibitors	62
Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial	62
The ongoing racial disparities in melanoma: An analysis of the Surveillance, Epidemiology, and End Results database (1975-2016)	62
COVID-19 and personal protective equipment: Treatment and prevention of skin conditions related to the occupational use of personal protective equipment	62
Overzealous hand hygiene during the COVID 19 pandemic causing an increased incidence of hand eczema among general population	62
Teledermatology in the wake of COVID-19: Advantages and challenges to continued care in a time of disarray	59
Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan	59
Association between alopecia areata, anxiety, and depression: A systematic review and meta-analysis	59
Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis	58
Cannabinoids for the treatment of chronic pruritus: A review	57
Infantile hemangioma. Part 2: Management	57
Delgocitinib ointment in pediatric patients with atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and a subsequent open-label, long-term study	57
American Academy of Dermatology Guidelines: Awareness of comorbidities associated with atopic dermatitis in adults	56
Guidelines of care for the management of actinic keratosis	56
Medical students’ ability to diagnose common dermatologic conditions in skin of color	55
The clinical spectrum of COVID-19–associated cutaneous manifestations: An Italian multicenter study of 200 adult patients	55
Immune checkpoint inhibitors to treat cutaneous malignancies	55
Rational hand hygiene during the coronavirus 2019 (COVID-19) pandemic	54
The American Academy of Dermatology COVID-19 registry: Crowdsourcing dermatology in the age of COVID-19	54
Visible light. Part II: Photoprotection against visible and ultraviolet light	53
Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis	53
Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis	52
Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis	52
Racial differences in time to treatment for melanoma	51
Management of inadequate response and adverse effects to dupilumab in atopic dermatitis	51
High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa	51
Role of phototherapy in the era of biologics	50
Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group	50
Treatment considerations for patients with pemphigus during the COVID-19 pandemic	50
Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa	49
Dupilumab improves clinical manifestations, symptoms, and quality of life in adult patients with chronic nodular prurigo	49
Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus	49
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry	49
Validation of a 40-gene expression profile test to predict metastatic risk in localized high-risk cutaneous squamous cell carcinoma	47
Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study	47
Diagnostic and management considerations for “maskne” in the era of COVID-19	46
IgA pemphigus: A systematic review	46
Evaluation of platelet-rich plasma as a treatment for androgenetic alopecia: A randomized controlled trial	46
Leprosy: Treatment and management of complications	45
Association between hidradenitis suppurativa, depression, anxiety, and suicidality: A systematic review and meta-analysis	45
The impact of demographics, socioeconomics, and health care access on melanoma outcomes	45
Itch: Pathogenesis and treatment	45
The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study	45
Prevalence estimates for pyoderma gangrenosum in the United States: An age- and sex-adjusted population analysis	44
Dermatologists in social media: A study on top influencers, posts, and user engagement	44
Natural language processing of Reddit data to evaluate dermatology patient experiences and therapeutics	44
The risk of respiratory tract infections and symptoms in psoriasis patients treated with interleukin 17 pathway–inhibiting biologics: A meta-estimate of pivotal trials relevant to decision making duri	43
Risk of hospitalization and death from COVID-19 infection in patients with chronic plaque psoriasis receiving a biologic treatment and renal transplant recipients in maintenance immunosuppressive trea	43
Treatment of pediatric alopecia areata: A systematic review	43
Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2	42
Mucocutaneous disease and related clinical characteristics in hospitalized children and adolescents with COVID-19 and multisystem inflammatory syndrome in children	42
Hair transplantation: Basic overview	42
Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients	41
The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: Systematic review and meta-analysis	41
One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trial	41
Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways	41
Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: A multicenter research network study	41
Axial psoriatic arthritis: An update for dermatologists	40
Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND)	40
Representation of dark skin images of common dermatologic conditions in educational resources: A cross-sectional analysis	40
Reflectance confocal microscopy	40
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study	40
Cross-sectional study of blood biomarkers of patients with moderate to severe alopecia areata reveals systemic immune and cardiovascular biomarker dysregulation	40
Psoriasis and mortality in the United States: Data from the National Health and Nutrition Examination Survey	39
Isolated nail lichen planus: An expert consensus on treatment of the classical form	39
When interferon tiptoes through COVID-19: Pernio-like lesions and their prognostic implications during SARS-CoV-2 infection	39
Dermatology without dermatologists? Analyzing Instagram influencers with dermatology-related hashtags	39
National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1	39
Cyclosporine therapy during the COVID-19 pandemic	39
Factors predictive of recurrence, metastasis, and death from primary basal cell carcinoma 2 cm or larger in diameter	39
Skin cancer: Primary, secondary, and tertiary prevention. Part I	39
Retrospective review of delayed adverse events secondary to treatment with a smooth, cohesive 20-mg/mL hyaluronic acid filler in 4500 patients	39
Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial	39
Treatment of erythrodermic psoriasis with biologics: A systematic review	38
Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata	38
Field cancerization: Treatment	38
The use of noninvasive imaging techniques in the diagnosis of melanoma: a prospective diagnostic accuracy study	38

Overview of TikTok's most viewed dermatologic content and assessment of its reliability	38
Inpatient teledermatology: Diagnostic and therapeutic concordance among a hospitalist, dermatologist, and teledermatologist using store-and-forward teledermatology	38
Comparison of a picosecond alexandrite laser versus a Q-switched alexandrite laser for the treatment of nevus of Ota: A randomized, split-lesion, controlled trial	38
Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign	37
Combination tofacitinib and oral minoxidil treatment for severe alopecia areata	37
Optimizing teledermatology visits for dermatology resident education during the COVID-19 pandemic	37
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: A network meta-analysis of clinical trial data	37
Association between rosacea and cardiometabolic disease: A systematic review and meta-analysis	37
TNF-α inhibitor–induced psoriasis: A decade of experience at the Cleveland Clinic	37
Impact of visible light on skin health: The role of antioxidants and free radical quenchers in skin protection	36
Outbreak of chilblain-like acral lesions in children in the metropolitan area of Milan, Italy, during the COVID-19 pandemic	36
Pyoderma gangrenosum in hematologic malignancies: A systematic review	36
Prevalence of asthma in patients with atopic dermatitis: A systematic review and meta-analysis	36
Insect repellents: An updated review for the clinician	36
Bias in, bias out: Underreporting and underrepresentation of diverse skin types in machine learning research for skin cancer detection—A scoping review	35
Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial	35
An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology	35
Improved patient access and outcomes with the integration of an eConsult program (teledermatology) within a large academic medical center	35
Dermoscopic features of basal cell carcinoma and its subtypes: A systematic review	35
Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry	35
Dipeptidyl-peptidase IV inhibitor–associated bullous pemphigoid: A systematic review and meta-analysis	35
Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study	34
Bullous pemphigoid after anti–programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes	34
The magnitude of COVID-19's effect on the timely management of melanoma and nonmelanoma skin cancers	34
Review of adverse cutaneous reactions of pharmacologic interventions for COVID-19: A guide for the dermatologist	34
Pain management in hidradenitis suppurativa and a proposed treatment algorithm	34
Association of atopic dermatitis severity with cognitive function in adults	34
Sexual transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A new possible route of infection?	33
Systemic sclerosis in adults. Part I: Clinical features and pathogenesis	33
Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial)	33
Outcomes and prognostic factors in African American and black patients with mycosis fungoides/Sézary syndrome: Retrospective analysis of 157 patients from a referral cancer center	33
Bidirectional association between alopecia areata and major depressive disorder among probands and unaffected siblings: A nationwide population-based study	33
Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults	33
Telemedicine for inpatient dermatology consultations in response to the COVID-19 pandemic	33
Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry	33
Fibrosing alopecia in a pattern distribution	33
Monkeypox emerges on a global scale: A historical review and dermatologic primer	33
New insights in COVID-19–associated chilblains: A comparative study with chilblain lupus erythematosus	33
The Alopecia Areata Consensus of Experts (ACE) study part II: Results of an international expert opinion on diagnosis and laboratory evaluation for alopecia areata	33
Difamilast ointment in adult patients with atopic dermatitis: A phase 3 randomized, double-blind, vehicle-controlled trial	33
Development of psoriasis during treatment with dupilumab: A systematic review	33
Drug reaction with eosinophilia and systemic symptoms (DRESS) in the pediatric population: A systematic review of the literature	32
Association between psoriasis and celiac disease: A systematic review and meta-analysis	32
Reply to “Varicella-like exanthem as a specific COVID-19-associated skin manifestation: Multicenter case series of 22 patients”: To consider varicella-like exanthem associated with COVID-19, virus var	32
Real-world comorbidities of atopic dermatitis in the pediatric ambulatory population in the United States	32
Diagnostic performance of artificial intelligence for histologic melanoma recognition compared to 18 international expert pathologists	32
Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison	32
Association of outdoor activity restriction and income loss with patient-reported outcomes of psoriasis during the COVID-19 pandemic: A web-based survey	32
Characterizing the role of dermatologists in developing artificial intelligence for assessment of skin cancer	32
The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Current and future approaches	32
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis	32
COVID-19 and biologics for psoriasis: A high-epidemic area experience—Bergamo, Lombardy, Italy	32
Vulvar diseases	32
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial	31
Itch: Epidemiology, clinical presentation, and diagnostic workup	31
Cumulative incidence and disease-specific survival of metastatic cutaneous squamous cell carcinoma: A nationwide cancer registry study	31
Autologous cell–based therapy for male and female pattern hair loss using dermal sheath cup cells: A randomized placebo-controlled double-blinded dose-finding clinical study	31
Health-related quality of life and economic burden of prurigo nodularis	31
Clinical benefit of baseline imaging in Merkel cell carcinoma: Analysis of 584 patients	30
Consulting ChatGPT: Ethical dilemmas in language model artificial intelligence	30
Incidence and outcomes of cutaneous angiosarcoma: A SEER population-based study	30
The rule of 10s versus the rule of 2s: High complication rates after conventional excision with postoperative margin assessment of specialty site versus trunk and proximal extremity melanomas	30
TikTok and dermatology: An opportunity for public health engagement	30
The impact of the COVID-19 pandemic on the presentation status of newly diagnosed melanoma: A single institution experience	30
Racial characteristics of alopecia areata in the United States	30
A phase 2b, randomized clinical trial of tapinarof cream for the treatment of plaque psoriasis: Secondary efficacy and patient-reported outcomes	29
Phase 2 trial of a neurokinin-1 receptor antagonist for the treatment of chronic itch in patients with epidermolysis bullosa: A randomized clinical trial	29
Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials	29
Narrow excision margins are appropriate for Merkel cell carcinoma when combined with adjuvant radiation: Analysis of 188 cases of localized disease and proposed management algorithm	29
Association between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: A population-based case-control study	29
Measuring atopic eczema symptoms in clinical practice: The first consensus statement from the Harmonising Outcome Measures for Eczema in clinical practice initiative	29
Time of onset and duration of post-COVID-19 acute telogen effluvium	29
The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study	28
Cutaneous adverse reactions to anti–PD-1 treatment—A systematic review	28
Janus kinase inhibitors in dermatology: Part I. A comprehensive review	28
Eruptions and related clinical course among 296 hospitalized adults with confirmed COVID-19	28
Bidirectional relationship between atopic dermatitis and inflammatory bowel disease: A systematic review and meta-analysis	28
Technological advances for the detection of melanoma	28
Deep learning for dermatologists: Part II. Current applications	27
Recommendations for phototherapy during the COVID-19 pandemic	27
Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment	27
Spironolactone for treatment of female pattern hair loss	27
Diffuse variants of scalp lichen planopilaris: Clinical, trichoscopic, and histopathologic features of 40 patients	27
Subepithelial autoimmune blistering dermatoses: Clinical features and diagnosis	27
Systematic review and meta-analysis of local recurrence rates of head and neck cutaneous melanomas after wide local excision, Mohs micrographic surgery, or staged excision	27
Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: A multicenter retrospective study of 59 cases	27
Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey	27
Expansion of asynchronous teledermatology during the COVID-19 pandemic	27
Long-term 2-year safety and efficacy of tralokinumab in adults with moderate-to-severe atopic dermatitis: Interim analysis of the ECZTEND open-label extension trial	27
Antecedent immunosuppressive therapy for immune-mediated inflammatory diseases in the setting of a COVID-19 outbreak	27
Early ultrasound for diagnosis and treatment of vascular adverse events with hyaluronic acid fillers	26
Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action	26
Multicenter prospective study on multivariant diagnostics of autoimmune bullous dermatoses using the BIOCHIP technology	26
Tofacitinib in the treatment of lichen planopilaris: A retrospective review	26
Participation bias, self-selection bias, and response bias	26